STAT3 and neoplasm: In the tumor microenvironment, hyperactivation of IL-6/JAK/STAT3 signaling pathway acts as a powerful suppressor of anti-tumor immune response and as a promotor of tumor progression, leading to a poor prognosis of cancer patients 30.